Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...
TherapeuticsMD, Inc. is an innovative pharmaceu...
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (â...
Lantheus Holdings, Inc. is the parent company o...
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage co...
AVROBIO, Inc., a leader in lentiviral-based gen...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the deve...
Pacira BioSciences, Inc. is a specialty pharmac...
Join the National Investor Network and get the latest information with your interests in mind.